Bausch + Lomb Announces New Scientific Data, Educational Events at the American Society of Cataract and Refractive Surgery Annual Meeting

Key Takeaways

• 45 presentations showcase B+L’s full ophthalmic portfolio.
• New data on ELIOS MIGS system, not yet US‑available.
• Multiple studies on enVista IOLs emphasize visual outcomes.
• Dry‑eye solutions MIEBO and Lifitegrast highlighted in real‑world evidence.
• Educational sessions address ophthalmology strategy and patient communication.

Summary

Bausch + Lomb announced it will present 45 scientific papers and posters at the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting in Washington, D.C., from April 9‑13, 2026. The sessions will feature data on its ELIOS minimally‑invasive glaucoma surgery system, enVista Envy and Aspire intra‑ocular lenses, MIEBO dry‑eye drops, ScoutPro osmolarity device, Stellaris laser platform, TENEO excimer laser, and lifitegrast solution. In addition to the scientific program, the company is hosting three educational events focused on ophthalmology strategy, patient communication, and modern cataract surgery techniques. The ELIOS procedure remains in development and is not yet marketed in the United States.

Pulse Analysis

The ASCRS meeting is the premier forum for cataract and refractive surgeons, drawing thousands of clinicians and industry leaders. Bausch + Lomb’s decision to unveil 45 abstracts underscores its commitment to shaping clinical practice and highlights a broad portfolio that spans glaucoma, intra‑ocular lenses, dry‑eye therapeutics, and laser platforms. By aligning scientific presentations with live educational sessions, the company maximizes exposure to both data‑driven insights and strategic discussions, positioning itself at the forefront of emerging surgical techniques and patient‑centric care.

Market analysts note that Bausch + Lomb’s focus on premium IOLs such as enVista Envy and Aspire aligns with a growing demand for extended depth‑of‑focus lenses that reduce dependence on glasses. Simultaneously, the inclusion of real‑world evidence for MIEBO and lifitegrast reflects heightened scrutiny from payers on dry‑eye treatments, a segment projected to exceed $5 billion globally by 2028. The ELIOS MIGS system, though not yet U.S.‑approved, signals the company’s ambition to capture a share of the minimally invasive glaucoma market, which is expanding as surgeons seek safer, office‑based options.

For investors, the breadth of data presented at ASCRS offers a tangible gauge of product performance and market traction ahead of regulatory milestones. Positive outcomes from multi‑center studies could accelerate adoption, bolster reimbursement pathways, and differentiate Bausch + Lomb from rivals like Alcon and Johnson & Johnson Vision. Moreover, the strategic educational events on communication and value creation suggest a proactive approach to influencing prescribing behavior, potentially translating into stronger sales pipelines and sustained revenue growth. Confidence in the company’s pipeline is likely to rise as peer‑reviewed results become publicly available.